Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03920254 · ClinicalTrials.gov registry record · Phase 2
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
A Phase 2 study, sponsored by Theravance Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03920254 is a Phase 2 study that was terminated before completion, run by Theravance Biopharma. The registered enrollment target is 46 participants.
The verdict
NCT03920254, a Phase 2 study, was terminated before completion, sponsored by Theravance Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157
Interventions
- DRUG TD-1473 Dose A
- DRUG TD-1473 Dose B
- DRUG TD-1473 Dose C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2021-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03920254
The ClinicalTrials.gov registry entry for NCT03920254 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TD-1473 Dose A is the first listed.
NCT03920254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03920254 about?
NCT03920254 is a clinical study titled "TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study". A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157
What is the current status of trial NCT03920254?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2020-07-23. Estimated completion is 2021-10-27.
What interventions are being tested in trial NCT03920254?
The interventions under investigation include: TD-1473 Dose A (DRUG), TD-1473 Dose B (DRUG), TD-1473 Dose C (DRUG).
Who is sponsoring clinical trial NCT03920254?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.